Biotech | December 09, 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
While Merck can appeal, Halozyme said it expects the order to hold
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Growing patent filings and tier-2 innovators reflect expanding national research base
Subscribe To Our Newsletter & Stay Updated
